Tokyo Medical University Hospital

Tokyo 1600023

7 studies enrolling now · 55 studies all time

What they study most

Alopecia Areata, Alzheimer Disease, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Atopic Dermatitis, Atrial Fibrillation, Biopsy, Fine-needle, Breast Cancer, Carcinoma, Non-Small-Cell Lung, Cognitive Dysfunction, Colitis, Ulcerative, Crohn Disease

Studies at this site

• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer — Recruiting now
• A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis — Recruiting now
• A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma — Recruiting now
• A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis — Recruiting now
• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — Recruiting now
• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — Recruiting now
• A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer — Recruiting now
• A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases — Recruiting now
• A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease — Running, not enrolling
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] — Running, not enrolling
• A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors — Running, not enrolling
• A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer — Running, not enrolling
• An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment — Running, not enrolling
• A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — Running, not enrolling
• A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
• A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis — Running, not enrolling
• Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 — Running, not enrolling
• A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis — Running, not enrolling
• Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1 — Running, not enrolling
• Vamikibart in Participants With Uveitic Macular Edema — Completed
• Long-Term PF-06651600 for the Treatment of Alopecia Areata — Completed
• A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease — Stopped early
• Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance — Running, not enrolling
• DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] — Completed
• A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease — Running, not enrolling
• A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) — Completed
• A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) — Stopped early
• Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC — Running, not enrolling
• MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) — Stopped early
• Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1) — Completed
• A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis — Stopped early
• A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck — Stopped early
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD) — Stopped early
• Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) — Stopped early
• A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia — Completed
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A — Completed
• Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure — Stopped early
• A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors — Completed
• A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B — Completed
• A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis — Completed
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors — Completed
• Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD) — Completed
• Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen — Completed
• A Study of JNJ-64304500 in Participants With Alopecia Areata — Withdrawn before enrolling
• EUS-FNB With ROSE Vs. EUS-FNB Without ROSE — Completed
• A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). — Stopped early
• A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) — Stopped early
• Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib — Stopped early